Assessment of Liver Fibrosis with Diffusion-Weighted Magnetic Resonance Imaging Using Different b-values in Chronic Viral Hepatitis Open Access

Hepatic fibrosis develops primarily as a consequence of chronic viral hepatitis (CVH). As fibrosis progresses, it can result in cirrhosis and end-stage liver diseases [1,2] making it vitally important to diagnose fibrosis before patients develop early or established cirrhosis. Liver biopsy is the gold standard for staging liver fibrosis and evaluating necroinflammatory changes [1,3]. However, liver biopsy is an invasive method and has inherent risks exemplified by bleeding. Additionally, biopsy is limited by interobserver variability and sampling error [4,5]. Because of these limitations, noninvasive methods, for instance current imaging modalities, e.g. transient elastography (fibroscan) and magnetic resonance (MR) elastography, and a fibrotest are being investigated for identifying and staging fibrosis [6,7,8,9,10]. More recently, the utility of diffusion-weighted MR imaging (MRI; DWI), an advanced MRI technique, in the detection and staging of liver fibrosis has also been evaluated.

The DWI is a specific MRI technique that evaluates the motion of, mainly, water protons in the tissue. The apparent diffusion coefficient (ADC) is the most frequently used DWI measure and provides useful information about inflammation, perfusion and local cell breakdown. The ADC map is calculated based on exponential fitting of DWI over multiple b-values and is used to measure diffusion quantitatively. Prior studies have shown that in liver fibrosis water diffusion may be diminished by extracellular collagen fibers and proteoglycans, thus, reduced ADC values have been reported for liver fibrosis [1,10,11,12,13,14,15,16,17,18]. These findings suggest DWI could be a useful imaging technique to evaluate fibrosis. In more recent studies, researchers examined the relationship between the stages of hepatic fibrosis and ADC values [1,14,15,16,19].

The goal of this study was to examine the efficacy of ADC values and to compare the reliability of different b-values (i.e. 100, 600, 1,000 s/mm²) in detecting and identifying significant liver fibrosis.

This prospective study was carried out between March 2007 and April 2009 with a study population of 44 patients (males: 28 and females: 16, age: 31-60 years) and a control group of 30 healthy participants (male: 21 and female: 9, age: 37-67 years). In the study population 30 patients had chronic hepatitis B, and 14 had chronic hepatitis C. The patient exclusion criterion was presence of steatosis or malignant liver lesions because both conditions can influence ADC values and could be confounding factors [20]. In patients with CVH, DWI was performed followed by a liver biopsy 3-24 h later. Written informed consent was obtained from each participant, and the Institutional Research Ethics committee approved the study.

MRI was done using a 1.5-tesla MR system (General Electric Healthcare, Milwaukee, Wis., USA). Before the DWI examinations, fat-saturated T1-weighted axial, T1 in- and out-of-phase, fat-saturated T2-weighted axial, and single-shot fast spin echo T2-weighted coronal images were performed. The DWI images were obtained at: b-values of 100, 600 and 1,000 s/mm²; TR/TE, 8,000/67-91; matrix, 128 × 128; NEX, 1.0; FOV, 24 cm; slice thickness, 5 mm; interslice gap, none; diffusion direction, all; acquisition time, 32 s; coil, torso.

Automatic voxel-by-voxel analysis on a workstation (Software version 2.0, General Electric Medical Systems, Milwaukee, Wis., USA) was used to obtain gray-scale and color-coded ADC maps for the b-values of 100, 600 and 1,000 s/mm². Maps of the liver parenchyma were evaluated by an experienced abdominal radiologist (E.K.). The ADC values were measured by locating 3 round regions of interest (ROIs) approximately 1 cm in diameter in the right lobe of the liver, excluding large vessels and motion artifacts (fig. 1, 2, 3). For each liver lobe, the final ADC value was calculated as the average of the ADC values obtained from the 3 ROIs.

Eighteen-gauge ultrasound-guided core biopsy was carried out on the right liver lobe. An experienced histopathologist (A.F.D) evaluated the specimens in accordance with the modified Ishak scoring system. The staging system scored fibrosis levels continuously from stage 0 to stage 6. The scores were identified as follows: F0 = no fibrosis; F1 = fibrous expansion of some portal areas with or without short fibrous septa; F2 = fibrous expansion of most portal areas with or without short fibrous septa; F3 = fibrous expansion of most portal areas with occasional portal-to-portal bridging; F4 = fibrous expansion of most portal areas with marked bridging (portal-to-portal as well as portal-central); F5 = marked bridging (portal-to-portal and/or portal-central) with occasional nodules (incomplete cirrhosis); F6 = cirrhosis (probable or definite) [21].

A receiver-operating characteristic (ROC) curve was used to evaluate ADC values and the stage of liver fibrosis. The ROC analysis was also performed to decide ADC cutoff values to differentiate liver fibrosis at 100, 600 and 1,000 s/mm² gradients. The optimal cutoff values that represented maximized test sensitivity and specificity using the Youden index were used. Sensitivity, specificity, positive and negative predictive values (PPV, NPV), and p values were determined using ROC analysis.

Of the 44 biopsies, 23 (52.2%) had Ishak scores of ≥3 while 21 (47.8%) had a score of ≤2. The mean ADC values of the study and the control groups did not differ significantly from each other at b-values of 100 s/mm² (3.69 ± 0.5 × 10^-3 vs. 3.7 ± 0.3 × 10^-3 mm²/s; p = 0.257) and 600 s/mm² (2.40 ± 0.3 × 10^-3 vs. 2.5 ± 0.5 × 10^-3 mm²/s; p = 0.345). However, at the b-value of 1,000 s/mm², the mean ADC value of the study group (0.99 ± 0.3 × 10^-3 mm²/s) was lower than that of the control group (1.2 ± 0.1 × 10^-3 mm²/s; table 1), and the difference was statistically significant (p = 0.001).

For the b-value of 1,000 s/mm², when the ADC value for the detection of liver fibrosis was accepted as ≤0.0011 mm²/s, the mean area under the ROC curve was 0.702 ± 0.07 (p = 0.0015). The sensitivity, specificity, PPV and NPV were 61.3, 80, 81.8 and 58.5%, respectively (table 2; fig. 4).

At the b-value of 1,000 s/mm², when ≤0.0011 mm²/s was accepted as the cutoff ADC value for the detection of significant liver fibrosis (Ishak score ≥3), the mean area under the ROC curve was 0.759 ± 0.07 (p = 0.0001). The sensitivity, specificity, PPV and NPV were 56.5, 93.3, 86.7 and 73.7%, respectively (table 2; fig. 5).

For the b-value of 1,000 s/mm², when the ADC cutoff value for the detection of fibrosis and significant liver fibrosis (Ishak score ≥3) was accepted as ≤0.0009 mm²/s, PPV values increased up to 100% but sensitivity and NPV values decreased (table 3).

In the current study the ADC values were effectively used to detect and identify significant liver fibrosis. Further, the b-value of 1,000 s/mm² was more reliable than b-values of 100 and 600 s/mm² for detecting fibrosis and significant fibrosis. The detection of significant fibrosis (Ishak score ≥3) is clinicallyessential because only patients with significant liver fibrosis are considered as suitable for antiviral treatment [22,23]. Patients with milder fibrosis, on the other hand, are often not given an aggressive treatment due to the cost and toxicification associated with antiviral treatment [22].

Our findings are in accordance with the study of Taouli et al. [1], which showed that ADC values drawn from DWI were useful for the evaluation of liver fibrosis at b-values of 500 s/mm² or larger. Using a sample larger than that of Taouli et al., we found that 1,000 s/mm² was more effective than the b-value of 600 s/mm² in detecting liver fibrosis. Our results are also in line with the study of Bakan et al. [16], in which ADC values obtained at the b-value of 1,000 s/mm² were found to be effective in identifying significant fibrosis. Bakan et al. further concluded that at a b-value of 1,000 s/mm² ADC values were helpful in differentiating between every combination of fibrosis stages except for F0 versus F1 and F1 versus F2.

Most studies that compared ADC values of fibrotic and normal livers found that patients with cirrhosis had lower ADC values than healthy participants [1,10,11,12,13,14,15,16,17,18]. Sandrasegaran et al. [15], using b-values of 50 and 400 s/mm², concluded that although there was a statistically significant difference between ADC values of cirrhotic and nonfibrotic liver, ADC values were not helpful in differentiating F2 fibrosis from lower or upper stages of fibrosis. On the other hand, Koinuma et al. [18] found a relationship between fibrosis scores and ADC values at b-values of 0 and 128 s/mm². In the study of Boulanger et al. [19] there was no statistically significant difference between ADC values of patients with hepatitis C and ADC values of the control group at 5 different b-values changing from 50 to 250 s/mm². When interpreting the results of these 3 studies, it is important to keep in mind other findings (e.g. Le Bihan et al. [24,25] and Yamada et al. [26]) that overestimated ADC values at lower b-values due to the perfusion effect. In the current study, to prevent such an overestimation larger b-values were used. Our findings suggest that ADC values at 1,000 s/mm² were more effective than ADC values at b-values of 100 and 600 s/mm² in detecting liver fibrosis.

Potential limitations of our study were that similar numbers of patients were not used at each stage of fibrosis and the activity score of hepatitis was not evaluated. Future studies with a larger sample that is distributed evenly among different stages of fibrosis are recommended although such studies could inevitably take a longer period of time than the current study.

Our findings showed that ADC values at 1,000 s/mm² were helpful in detecting liver fibrosis. However, b-values <600 s/mm² could not accurately quantify liver fibrosis. Based on the accurate detection of significant fibrosis, the use of ADC values at 1,000 s/mm² could potentially be useful in making a decision about antiviral treatment.